Employee Costs and Workforce - As of December 31, 2022, the group had approximately 1,106 employees, with total employee costs amounting to RMB 183,630,000, an increase from RMB 172,023,000 in 2021[1]. - The total employee benefits expense, including salaries and wages, increased to RMB 183,630,000 in 2022 from RMB 172,023,000 in 2021, representing a growth of about 6.5%[128]. Financial Performance - The company's total sales for the year ended December 31, 2022, were approximately RMB 1,277,682,000, representing a growth of 9.7% year-on-year, with an increase of RMB 112,527,000[25]. - The revenue for the year ended December 31, 2022, was approximately RMB 1,277,682,000, representing a 9.7% increase from RMB 1,165,155,000 in 2021[59]. - The operating profit for the year was RMB 380,292,000, reflecting a 13.5% increase from RMB 335,085,000 in 2021[59]. - The net profit attributable to the owners of the parent company was RMB 358,057,000, slightly down by 0.03% from RMB 358,175,000 in the previous year[57]. - The company reported a pre-tax profit of RMB 438,408,000, a slight decrease of 0.2% from RMB 439,323,000 in 2021[59]. - The total comprehensive income for the year 2022, after tax, was RMB 364,256,000, compared to RMB 353,219,000 in 2021, indicating an increase of 3.0%[163]. Sales and Revenue Breakdown - The sales of finished drugs amounted to RMB 1,137,241,000, an increase of 12.7% compared to the previous year, accounting for approximately 89.0% of total sales, up by 2.4 percentage points[25][27]. - Revenue from pharmaceutical product sales was RMB 1,276,505,000 in 2022, compared to RMB 1,159,680,000 in 2021, indicating a year-over-year increase of about 10.1%[101]. - Revenue from external customers in mainland China for 2022 was RMB 1,218,740,000, up from RMB 1,102,806,000 in 2021, representing a growth of approximately 10.5%[86]. - The sales of specialty drugs showed significant year-on-year growth, driven by the continued rise in sales of Entecavir dispersible tablets and Atorvastatin calcium tablets[31]. - The sales volume of the antiviral drug Entecavir dispersible tablets grew by 19.5%, with revenue increasing by 47.0% year-on-year[39]. - The sales of atorvastatin calcium tablets reached RMB 270,368,000, up from RMB 255,059,000 in the previous year, making up 21.2% of total sales[41]. Dividends and Shareholder Returns - The board proposed a final dividend of HKD 0.073 per share, subject to shareholder approval at the annual general meeting on May 25, 2023[13]. - The company plans to distribute a final dividend of HKD 0.073 per share, totaling approximately HKD 109,412,000, which represents a payout ratio of about 32.4%, an increase of 5.1 percentage points year-on-year[28]. - The company declared a proposed final dividend of HKD 0.073 per share for 2022, compared to HKD 0.065 per share in 2021, reflecting an increase of about 12.3%[139]. Research and Development - In 2022, the group submitted registrations for 9 products to the National Medical Products Administration, including 7 supplementary applications and 1 active pharmaceutical ingredient registration[22]. - The company received two invention patents in 2022, enhancing its intellectual property portfolio[23]. - Research and development costs for the year were RMB 79,478,000, compared to RMB 67,028,000 in 2021[61]. - The establishment of the Advanced Technology Research Institute in June 2022 aims to optimize R&D resources and attract external talent for drug development[36]. - The company plans to accelerate its R&D, production, and sales efforts to adapt to national healthcare reforms and industry developments[37]. Assets and Liabilities - Total assets as of December 31, 2022, amounted to RMB 3,672,643,000, an increase from RMB 3,339,558,000 as of December 31, 2021[85]. - Total liabilities increased to RMB 1,012,776 thousand in 2022 from RMB 941,697 thousand in 2021, reflecting an increase of 7.5%[68]. - The company's total equity reached RMB 2,649,867 thousand in 2022, compared to RMB 2,397,861 thousand in 2021, indicating a growth of 10.5%[70]. - Current assets rose to RMB 1,743,995 thousand in 2022, up from RMB 1,511,036 thousand in 2021, marking an increase of 15.4%[68]. - Non-current assets increased to RMB 1,928,648 thousand in 2022 from RMB 1,828,522 thousand in 2021, representing a growth of 5.5%[68]. Operational Challenges - The company faced operational challenges due to the ongoing COVID-19 pandemic and geopolitical uncertainties, but maintained operations with the support of its employees[29]. - The sales of intermediates and raw materials decreased by 10.0% year-on-year to RMB 140,441,000, primarily due to the impact of the COVID-19 pandemic[25]. Investments and Future Plans - The group has no major future investment plans or capital asset purchases beyond disclosed capital expenditures and relocation plans[6]. - The company signed a shareholder loan agreement to provide a total of RMB 105,000,000 to 康融东方 in three installments to support project development[32]. - The company received government compensation of RMB 82,433,000 for the relocation of its antibiotic production facility[33]. - The company is optimistic about the future prospects of its investments based on clinical trial progress and market conditions[32]. Miscellaneous - The group had no significant contingent liabilities as of December 31, 2022[2]. - There were no assets pledged to banks for credit facilities as of December 31, 2022[3]. - The group reported a capital expenditure of RMB 231,269,000 for the year, compared to RMB 587,059,000 in the previous year[86]. - The company incurred a loss of RMB 61,905,000 from its investment in the joint venture 康融东方 due to high clinical trial costs[32].
东瑞制药(02348) - 2022 - 年度业绩